SCHEMBL3531305

SCHEMBL3531305

COc1ccc(S(=O)(=O)Nc2ccc(Cl)nc2I)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 4/20 0.56
NFE2L2 Q16236 2/20 0.56
SQSTM1 Q13501 1/20 0.56
LMNA P02545 3/20 0.53
FFAR4 Q5NUL3 2/20 0.52
GLO1 Q04760 1/20 0.50
SLC40A1 Q9NP59 1/20 0.50
KDM1A O60341 1/20 0.49
MAOA P21397 1/20 0.49
HPGD P15428 3/20 0.49
TSHR P16473 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MITF O75030 1/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535998 0.85 NFE2L2 (0.61) KEAP1NFE2L2LMNAFFAR4GLO1
SCHEMBL3527028 0.82 CCR2 (0.48) LMNASLC40A1ALDH1A1TP53GAA
SCHEMBL3535146 0.81 SLC40A1 (0.61) KEAP1GLO1SLC40A1GAAMAPT
SCHEMBL3531183 0.81 ALDH1A1 (0.61) LMNAHPGDALDH1A1TP53GAA
SCHEMBL3529529 0.81 KMT2A (0.49) LMNASLC40A1HPGDALDH1A1GAA
SCHEMBL3530032 0.78 APP (0.42) FFAR4SLC40A1ALDH1A1MAPT
SCHEMBL8629640 0.78 TUBB4A (0.55) KEAP1NFE2L2SQSTM1LMNAGLO1
SCHEMBL7594141 0.75 LMNA (0.67) KEAP1NFE2L2SQSTM1LMNAFFAR4
SCHEMBL3533105 0.73 SLC40A1 (0.55) KEAP1NFE2L2GLO1SLC40A1GAA
SCHEMBL12768028 0.73 KEAP1 (0.81) KEAP1NFE2L2SQSTM1LMNAFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
EP-1919474-B1 PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS FOURNIER LAB SA (FR) 2009-08-05 EP disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG KEAP1 3928/4885NFE2L2 2615/4885SQSTM1 3589/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP KEAP1 758/4885NFE2L2 1208/4885SQSTM1 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.